Alyssum Therapeutics
PrivateLast Round
Series A
Jan 8, 2025
Total Funding Raised
$58.88M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Alyssum Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series A round in January 2025.
Alyssum Therapeutics is a biotechnology company developing first-in-class molecules that modulate the B cell immune response to treat cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alyssum Therapeutics Comparables
Compare Alyssum Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ENB Therapeutics | 77% | |
| Bespoke Biotherapeutics | 75% | |
| ImmuneSensor Therapeutics | 74% |
For institutional investors. Book with your work email.
Alyssum Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 8, 2025 | ||||
| Series A | Oct 23, 2024 | ||||
| Series A | May 28, 2013 | ||||
| Seed | Jul 2, 2012 |
For institutional investors. Book with your work email.
Alyssum Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Navam Capital | Seed, Series A |
| Famy Finance | Series A |
| Aarin Capital Partners | Series A |
| FemHealth Ventures | Series A |
| Accel | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 181% MoM.
- Jan 8, 2025
$28M Series A round completed.
For institutional investors. Book with your work email.
Alyssum Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Alyssum Therapeutics's valuation, stock price, and market status.
Is Alyssum Therapeutics a public or private company?
Alyssum Therapeutics is a private company.
What is the current stock price of Alyssum Therapeutics?
Alyssum Therapeutics is a private company, so its shares have no public market price. Caplight tracks Alyssum Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Alyssum Therapeutics worth (valuation)?
Valuation information for Alyssum Therapeutics is not publicly available.
Can I buy Alyssum Therapeutics stock?
Alyssum Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Alyssum Therapeutics's last funding round?
Alyssum Therapeutics's most recent funding round was Series A on January 8, 2025.
Who are the main investors in Alyssum Therapeutics?
Key investors in Alyssum Therapeutics include Navam Capital, Famy Finance, Aarin Capital Partners, FemHealth Ventures.
Will Alyssum Therapeutics IPO soon?
No public IPO plans have been announced for Alyssum Therapeutics.
How can I track Alyssum Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Alyssum Therapeutics's shares on secondary markets.